OXB 201
Alternative Names: Angiostatin endostatin gene therapy - Oxford BioMedica; Angiostatin lentivector gene therapy; EIAV.angiostatin - Oxford bioMedica; EIAV.endostatin - Oxford BioMedica; Endostatin lentivector gene therapy; OXB-201; RetinoStatLatest Information Update: 05 Nov 2023
At a glance
- Originator Oxford BioMedica
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 27 Jul 2022 Discontinued - Phase-I for Wet age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous) (Oxford BioMedica pipeline, July 2022)
- 07 May 2020 Suspended - Phase-I for Wet age-related macular degeneration (In the elderly, In adults) in USA (Intravitreous)
- 23 Mar 2020 Angiostatin endostatin gene therapy is still in phase I development for Wet age related macular degeneration (In the elderly, In adults) in USA (Intravitreous, Injection) (Oxford BioMedica pipeline, March 2020)